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Abstract
Aim: alculate time to first-line treatment failure, annual cost and cost-effectiveness of NNRTI versus PIboosted first-line
HAART regimens in the UK, 1996–2006.
Background: Population costs for HIV services are increasing in the UK and interventions need to be effective and efficient
to reduce or stabilize costs. 2NRTIs + NNRTI regimens are cost-effective regimens for first-line HAART, but these regimens
have not been compared with first-line PIboosted regimens.
Methods: Times to first-line treatment failure and annual costs were calculated for first-line HAART regimens by CD4 count
when starting HAART (2006 UK prices). Cost-effectiveness of 2NRTIs+NNRTI versus 2NRTIs+PIboosted regimens was calculated
for four CD4 strata.
Results: 55% of 5,541 people living with HIV (PLHIV) started HAART with CD4 count #200 cells/mm3, many of whom were
Black Africans. Annual treatment cost decreased as CD4 count increased; most marked differences were observed between
starting HAART with CD4 #200 cells/mm3 compared with CD4 count .200 cells/mm3. 2NRTI+PIboosted and 2NRTI+NNRTI
regimens were the most effective regimens across the four CD4 strata; 2NRTI+NNRTI was cost-saving or cost-effective
compared with 2NRTI + PIboosted regimens.
Conclusion: To ensure more effective and efficient provision of HIV services, 2NRTI+NNRTI should be started as first-line
HAART regimen at CD4 counts #350 cell/mm3, unless specific contra-indications exist. This will increase the number of
PLHIV receiving HAART and will initially increase population costs of providing HIV services. However, starting PLHIV earlier
on cost-effective regimens will maintain them in better health and use fewer health or social services, thereby generating
fewer treatment and care costs, enabling them to remain socially and economically active members of society. This does
raise a number of ethical issues, which will have to be acknowledged and addressed, especially in countries with limited
resources.
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Introduction
A recent study indicated that the population cost for providing
HIV services in the UK has increased considerably and is likely to
continue to do so if cost cutting measures are not introduced [1].
One way of reducing cost, is by using the most efficient treatment
regimens. The outcome and cost-effectiveness of highly active
antiretroviral therapy (HAART) regimens were recently analysed
for the period 1996 – 2002. Two nucleoside reverse transcriptase
inhibitors comparing non-nucleoside reverse transcriptase inhib-
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e20200
Citor (2NRTIs+NNRTI) were compared with 2NRTIs and protease
inhibitor (PI) containing regimens for first-, second- or third-line
treatment for people living with HIV (PLHIV) in the UK [2]. This
analysis demonstrated that 2NRTIs+NNRTI regimens were cost-
effective regimens for first-, second- or third-line HAART.
However, only relatively few patients had been started on PIboosted
regimens nor did that analysis investigate differences in the use,
cost and outcome of treatment for those patients who started
HAART regimens at different CD4 counts. The aim of this study
was to investigate the cost-effectiveness of NNRTI containing first-
line regimens compared with PIboosted regimens for PLHIV
starting at different levels of CD4 count during the period 1996–
2006 in the UK.
Methods
The National Prospective Monitoring System on the use, cost
and outcome of HIV service provision in UK hospitals - HIV
Health-economics Collaboration (NPMS-HHC) has been moni-
toring prospectively the effectiveness, efficiency, equity and
acceptability of treatment and care in participating HIV units
since 1996. Using an agreed minimum dataset, standardised data
are routinely collected in clinics and transferred to the NPMS-
HHC Coordinating and Analytic Centre (CAC). As the data are
transferred in pseudo-anonymized format, patient consent is not
required according to the UK Department of Health, which are in
line with international guidelines [3]. While ensuring patient and
clinic confidentiality, the data are analysed at clinic and aggregate
levels: clinic specific analyses remain confidential, while aggregate
analyses become public documents [4,5].
Information on the use of hospital inpatient (IP), outpatient (OP)
and dayward services between 1
st January 1996 and 31
st
December 2006, was obtained from computerized information
systems from 14 UK hospitals participating in this analysis.
HAART became routinely available in the NPMS-HHC clinics in
1996, and subjects who started HAART since then were included
in the study. Patients who were transferred from another HIV unit
were excluded as it was not possible to establish whether the
available HAART combination was indeed their first line regimen.
As this study investigated the cost-effectiveness between these
regimens when starting at four different CD4 count strata, PLHIV
were stratified into four categories based on their CD4 count when
starting HAART: #100; 101–200; 201–350 and .350 cells/
mm3; those with unavailable CD4 count within 4 month before or
after starting HAART were excluded from this analysis.
Use and cost of services
The mean numbers of IP days, OP visits and dayward visits per
patient-year (PPY) were calculated for first-line HAART and were
stratified by type of regimen. A patient-year was defined as 365.25
days of follow up. The denominator consisted of the total duration
of follow up for all patients during the period of first-line treatment
with HAART, from when they were first seen till the end of the
respective study period if still alive and on first-line HAART, or
when they failed first-line HAART or died, or if they were lost to
follow up, which ever came first. Numerators were calculated by
summing the use of IP, OP or dayward services when on first-line
HAART. Mean use of services PPY were calculated using the
Poisson regression test for the total population who started first-
line HAART as well as for the specified sub-populations
disaggregated by CD4 count when starting HAART. The mean
use of services was calculated based on a method for calculating
the use of services employed in previous studies [1,2,6,7] and
summarised by the formula:
M~
P n
i~1
P k
j~1
Sij
P n
i~1
P k
j~1
tij{ti j{1 ðÞ ðÞ
|365:25
Where n = total number of individuals; k = day of
censoring;Sij= use of service of individual i at jth day; tij =
number of days starting and remaining on first-line HAART by
CD4 stratum forindividual I; M = mean of services S per patient-
year by CD4 stratum.
First-line HAART failure was defined as any change made to
the HAART containing regimen, which included intensification of
regimen by adding any anti-retroviral drug to the regimen or
swapping the NNRTI or a PI to another anti-retroviral drug class.
Dropping a NRTI, NNRTI or PI alone or simplification of ARV
combination with no other changes made to the regimen did not
constitute treatment failure. Causes for failure included clinical,
immunological or virological reasons and others, where adverse
effects were the most likely cause [8].
The unit cost for an average IP day was £475, £94 for an OP
visit and £384 per dayward visit [9]. IP, OP and dayward costs
were obtained by multiplying their mean number of IP days, OP
and dayward visits PPY by their respective unit costs for PLHIVs
starting at different CD4 counts. The costs generated by the use
of services for each of the CD4 categories were added to the costs
of HAART, ‘other’ drugs, tests and procedures performed [9].
The costs for the different HAART regimens were weighted
average annual prices based on prices negotiated by the London
HIV Consortium in 2006 with pharmaceutical companies. The
study was performed from a public service perspective [10] and
costs for use of services, ‘other’ drugs, tests and procedures
performed, were obtained from the 2008 NPMS-HHC report
[9]. Costs were calculated in UK pounds (2006 prices) and time
to first-line failure and treatment costs were discounted at 3.0%
per annum [11].
Regression Models and Time-to-Treatment Failure
Parametric quantitative data are presented as means with
standard deviation (SD) while non-parametric data are presented
as medians with inter-quartile range (IQR). Between group
comparisons of parametric data were tested using one-way-
ANOVA while between group comparisons of non-parametric
data were tested using the Kruskal-Wallis test. Qualitative data by
CD4 count strata were tested using the x
2 test and where
appropriate these were adjusted by Yates’ correction.
Median and inter-quartile ranges were used to create grouped
categories, including a separate category for all variables with
missing data. This ensured no degrees of freedom were lost when
building multivariable models. Cox’s proportional hazards regres-
sion models with single variables were initially used to estimate
likelihood of treatment failure. All variables found to have a
probability of p,0.2 in univariate Cox’s proportional hazards
model were used to build a multivariable model to assess the risk of
a particular prognostic variable while controlling for the other
variables in the model. The final multivariable model presented
was tested for its distributional assumptions using Cox Snell
residual plots and adjusted for gender, age, baseline viral load,
baseline CD4 count, stage of HIV infection and stratified by year
of starting first line HAART for possible confounding or residual
effects. Baseline viral load and CD4 cell count were defined as
those available 4 months before or after starting first-line HAART
and baseline clinical stage was based on the diagnosis within 30
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treatment failure derived from patient days of follow up. A patient
day of follow-up was estimated from start of study period of 1
st
January 1996, or if entry to cohort came after this date then entry
into the cohort date to either the end of the study period of 31
st
December 2006, failure of HAART regimen, or the last recorded
visit during their follow-up.
Analyses of each of four CD4 strata were adjusted for
potential confounding or residual effects of sex, age, baseline
viral load, baseline CD4 count, stage of HIV infection at start of
HAART regimens and stratified by year of starting first-line
HAART.
Survival Function Estimation
After adjusting for confounding and residual variables in the
final model, the PROC PHREG in SAS was run with the
BASELINE statement to create a new data set with the ‘‘survival’’
function estimates at the event times of each stratum for each list of
variables in the final multivariable model [12]. This contained the
‘‘survival’’ function estimates corresponding to the means of the
variables in the model for each stratum. The resulting survival
function estimates were used to model with event time as a
covariate using the least squares maximum likelihood model. The
resulting least squares regression model was then used to estimate
the extrapolated median and inter quartile ranges (IQR) of time to
treatment failure. All analyses were performed using SAS version
9.1.3 statistical software and all significance tests presented are
two-tailed.
Life year gained for first-line HAART regimens
Based on differences in the estimated failure times, the
additional life years gained on first-line (LYG-FL) HAART
regimens were calculated comparing 2NTRIs+NNRTI regimens
with 2NRTIs+PIboosted based on methods used for previous
analyses [2,13,14]. The incremental cost-effectiveness ratios
(ICERs) were calculated using time to first-line failure as outcome
measure and based on the following formula [10]:
ICER~ CostsA{CostsB ½  = OutcomeA{OutcomeB ½ 
A cost-effectiveness analysis was produced for each of the four
CD4 categories.
Results
Population characteristics
During the study period, 7600 PLHIV were identified as being
on first-line therapy. For 5541 (73%) the CD4 count when starting
first-line HAART could be identified. Of the 5541 PLHIVs, 18%
failed first-line HAART during the study period; 77% of all
PLHIV were men, 59% were Caucasians, 22% Black Africans and
16% were from other ethnic groups. Mean age at start of therapy
varied between baseline CD4 count strata from 37.4 (SD 8.9) to
38.2 (SD 8.7) years and 187 PLHIVs were known to be or have
been injecting drug users (Table 1).
The median time between diagnosis of HIV infection and
starting HAART for the whole population was 1.6 years (IQR 0.2
to 5.6 years). For those with a CD4 count #100 cells/mm3, the
time interval between diagnosis of HIV infection was 0.3 years
(IQR 0.1 to 4.9), which increased to 2.4 years (IQR 0.4 to 5.9) for
those with a CD4 count .350 cells/mm3 (Krukal-Wallis p,
0.001; Table 1). Of all PLHIVs, 55% started HAART with a CD4
count #200 cells/mm3. Of those who started with a CD4 count
#200 cells/mm3, 23% were Black Africans and 49% were
Caucasians, which compared with 17% Black African and 60%
Caucasians respectively who started with a CD4 count .200
cells/mm3 (X
2
2=72.6, p,0.001; Table 1).
Estimated time to first-line treatment failure
PLHIV on 2NRTI’s + PIboosted or 2NRTI’s + NNRTIs were
less likely to fail than those that started on other combinations.
Across all CD4 strata, estimated median time to first-line failure
Table 1. Demographic characteristics of PLHIV starting HAART at various CD4 count categories (cells/mm3) and time interval
between diagnosis of HIV and starting HAART.
Baseline
CD4 #100
N=1547 (%)
Baseline
CD4 101–200
N=1503 (%)
Baseline
CD4 201–350
N=1815 (%)
Baseline
CD4 .350
N=676 (%) p-value
Sex
Unknown
Female
Male
5 (0.3)
409 (26.4)
1133 (73.2)
1 (0.1)
347 (23.1)
1155 (76.8)
2 (0.1)
385 (21.2)
1428 (78.7)
2 (0.3)
140 (20.7)
534 (79.0)
,0.001
Mean Age (SD)
at start of therapy
38.2 (8.7) 38.2 (8.4) 37.4 (8.9) 37.0 (8.6) 0.265
Ethnic group
Not available
Other
Black African
Caucasian
163 (10.5)
309 (20.0)
385 (24.9)
690 (44.6)
110 (7.3)
264 (17.6)
326 (21.7)
803 (53.4)
112 (6.2)
288 (15.9)
323 (17.8)
1092 (60.2)
47 (7.0)
116 (17.2)
103 (15.2)
410 (60.7)
,0.001
IDU
Yes
No
58 (3.7)
1489 (96.3)
51 (3.4)
1452 (96.6)
56 (3.1)
1759 (96.9)
24 (3.6)
652 (96.4)
0.816
Median Duration
(IQR) since HIV
diagnosis to start of
first line therapy (years)
0.28 (0.08 TO 4.91)
Range: 0.00 to 96.48
1.56 (0.19 TO 5.63)
Range: 0.00 to 21.17
2.20 (0.45 to 6.00)
Range: 0.00 to 98.92
2.35 (0.42 to 5.88)
Range: 0.00 to 20.17
,0.001
doi:10.1371/journal.pone.0020200.t001
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9.0 to 28.1) compared with an estimated median of 13.9 years
(IQR 6.3 to 19.9) for those starting on 2NRTI’s + NNRTI.
When stratified at a CD4 count of 200 cells/mm3, results were
similar for those obtained for the total population, with the
2NRTIs + NNRTI and 2NRTI+PIboosted regimens being most
effective compared with other regimens. For PLHIV starting on
2NRTI’s + PIboosted with CD4 counts #200 cells/mm3, estimated
median time to first-line failure was 18.5 years (IQR 9.0 to 28.1)
compared with 14.7 years (IQR 6.6 to 22.9) for PLHIV starting on
2NRTIs + NNRTI regimens (Hazard ratio =0.5; 95%CI 0.32 to
0.78, p=0.002). For those PLHIV starting on 2NRTI’s + PIboosted
with a CD4 counts .200 cells/mm3, estimated median time to
first-line failure was 13.1 years (IQR 6.3 to 19.9) compared with
13.9 years (IQR 6.5 to 21.3) for those starting on 2NRTIs +
NNRTI regimens (Hazard ratio=0.9; 95%CI 0.57 to 1.41,
p=0.642).
When CD4 counts were stratified into four strata, the 2NRTIs +
PIboosted regimens had a longer estimated time to first-line failure
compared with 2NRTIs + NNRTI regimens only for those
PLHIV who started HAART with a CD4 count between 101–200
cell/mm3. For the other three strata, the 2NRTIs + NNRTI
regimens had similar or longer estimated times to first-line failure
(Table 2; Figures 1–4). In addition to the impact of the
antiretroviral drugs, women, younger people and those with an
AIDS diagnosis were all more likely to fail first-line therapy
(Table 2).
Annual cost of treatment and care
Those PLHIV with CD4 counts .200 cells/mm3 had fewer IP
days compared with those starting HAART with a CD4 count
#200 cells/mm3. When analyzed across the four CD4 strata, the
mean number of IP days was highest for those PLHIV who started
HAART with #100 cells/mm3 and IP days decreased as CD4
count increased (Table 3). Similar differences were observed for
the mean number of OP and dayward visits, though less
pronounced than for IP days. Across all CD4 strata, PLHIV on
2NTRIs+NNRTI used fewer services than those who started on
2NTRIs+PIboosted regimens (Table 3).
For all CD4 strata the annual treatment and care costs of
PLHIV on 2NRTIs + NNRT regimens were less compared with
those on 2NRTIs + PIboosted,. While annual costs decreased with
increasing CD4 count, the greatest difference in annual costs was
observed between those people who started HAART with a CD4
count #200 cells/mm3 compared with those with a CD4 count
.200 cells/mm3 (Table 3).
Cost-effectiveness of NNRTI versus PIboosted regimens
Both NNRTI and PIboosted regimens were effective first-line
regimens. However 2NRTIs+NNRTI regimens were cost-saving
for PLHIV starting on HAART with CD4 counts #100 cells/
mm3 and between 201–350 CD4 cells/mm3. For those starting
HAART with a CD4 count .350 cells/mm3, the cost per
additional life-year gained in first-line therapy on 2NRTIs+
NNRTI was £10,165; for those who started with CD4 counts
between 101–200 cells/mm3, the cost of an additional life-year
gained on 2NRTIs+PIboosted regimens was £35,361 (Table 3).
Discussion
The 2NRTI + NNRTI and 2NRTI + PIboosted regimens were
the most effective first-line HAART regimens. The annual
treatment costs were less for those managed with 2NRTIs +
NNRTI compared with 2NRTIs + PIboosted. Not only were drug
cost less for 2NRTIs + NNRTI regimens, these patients also used
fewer hospital services, resulting in lower annual treatment costs.
For three of the four CD4 strata, 2NRTIs + NNRTI regimens
were either cost-saving or cost-effective compared with 2NRTIs +
PIboosted regimens. Only when HAART was started at a CD4
count between 101–200 cells/mm3 did 2NRTIs + PIboosted
regimens have a longer time-to-first-line failure but at a cost of
£35,361 per additional first-line life-year gained. Similarly, for
those who started 2NRTIs + PIboosted regimens with CD4 count
#200 cells/mm3, the cost per life-year-gained was £39,533
compared with 2NRTIs + NNRTI regimens, while 2NRTIs +
Figure 1. Proportion of people starting HAART at CD4 count #100 cells/mm3 who failed first-line therapy and time to treatment
failure (days) comparing 2NRTIs+NNRTI with 2NRTIs+PIboosted first-line regimens.
doi:10.1371/journal.pone.0020200.g001
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PIboosted regimens with CD4 counts .200 cells/mm3 [15]. Both
£35,361 and £39,533 costs per additional first-line life-year
gained are above the £35,000 cut-off point, at which NICE
considers interventions not to be cost-effective [16].
While these analyses were based on a large number of subjects
followed-up over years, the analyses have limitations. Firstly, the
data were collected in 14 sites, 7 London and 7 out-of London
hospitals, but 91% of patients contributing to this study, were seen
in London sites. Secondly first CD4 count when starting HAART
could not be retrieved for all those who were identified as starting
first-line and 27% of patients had to be excluded. Thirdly, the
number of PLHIV starting on HAART with CD4 count .350
cells/mm3 were considerably less than those starting with a CD4
count #350 cells/mm3. This may increase with changing clinical
practice for initiating HAART and longer follow-up, but given the
similarity of results with those starting with CD4 count between
201–350 cells/mm3, the results may not change. Fourth, the data
Figure 2. Proportion of people starting HAART at CD4 counts 101 – 200 cells/mm3 who failed first-line therapy and time to
treatment failure (days) comparing 2NRTIs+NNRTI with 2NRTIs+PIboosted first-line regimens.
doi:10.1371/journal.pone.0020200.g002
Figure 3. Proportion of people starting HAART at CD4 count 201 – 350 cells/mm3 who failed first-line therapy and time to
treatment failure (days) comparing 2NRTIs+NNRTI with 2NRTIs+PIboosted first-line regimens.
doi:10.1371/journal.pone.0020200.g003
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PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e20200Figure 4. Proportion of people starting HAART at CD4 count .350 cells/mm3 who failed first-line therapy and time to treatment
failure (days) comparing 2NRTIs+NNRTI with 2NRTIs+PIboosted first-line regimens.
doi:10.1371/journal.pone.0020200.g004
Table 3. Mean number of inpatient Days, outpatient and dayward visits for PLHIV on different first-line HAART regimens, annual
cost for different HAART regimens and cost-effectiveness analyses comparing 2NRTIs+NNRTI and 2NRTIs+PIboosted for different CD4
count categories (2006 UK prices).
Baseline CD4 #100
N=1547
Baseline CD4 101-200
N=1503
Baseline CD4 201-350
N=1815
Baseline CD4 .350
N=676
Mean number of Inpatient Days for different HAART regimens
2NRTIs+PI
2NRTIs+2PI
2NRTIs+PIboosted
2NRTIs+NNRTI
8.70
2.34
6.07
3.47
4.42
6.44
1.89
1.72
1.60
3.21
2.57
1.14
2.01
2.89
1.74
1.26
Mean number of Outpatient Visits for different HAART regimens
2NRTIs+PI
2NRTIs+2PI
2NRTIs+PIboosted
2NRTIs+NNRTI
12.47
10.86
11.38
8.95
11.65
12.22
10.24
7.33
10.76
4.1
10.59
8.11
10.87
10.74
11.35
8.56
Mean number of Dayward Visits for different HAART regimens
2NRTIs+PI
2NRTIs+2PI
2NRTIs+PIboosted
2NRTIs+NNRTI
1.44
0.00
0.61
0.14
1.53
0.00
0.25
0.09
0.18
0.00
0.14
0.11
1.55
0.00
0.36
0.13
Annual cost of Treatment and care for different HAART regimens
2NRTIs+PI
2NRTIs+2PI
2NRTIs+PIboosted
2NRTIs+NNRTI
£25,751
£27,306
£24,556
£20,730
£23,679
£29,381
£22,327
£19,722
£14,816
£20,158
£15,721
£12,605
£15,544
£20,633
£15,478
£12,713
Cost-effectiveness of NNRTI versus PIboosted Regimens
2NRTIs+NNRTI
versus
2NRTIs+PIboosted
Saves £35,194 per annum
of first line HAART
----------- Saves £37,529 per annum of first
line HAART
£10,165 per added year of first
line HAART
2NRTIs+PIboosted
versus
2NRTIs+NNRTI
---------
£35,361 per added year of first line
HAART
--------------- --------------
doi:10.1371/journal.pone.0020200.t003
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data [17]. While results were adjusted for a number of key
potential confounders, some residual confounding may have
remained and affected the results.
Despite these limitations, lessons can be drawn from these
analyses. The annual cost of treatment and care were less for those
starting HAART with higher CD4 counts, partly due to less
inpatient care. While a gradual decrease in annual treatment costs
are observed with increasing CD4 count, the most marked cost
differences were observed between those who start with a CD4
count #200 cells/mm3 compared with those with a CD4 count
.200 cells/mm3. Recent Canadian and US studies produced
similar results, where PLHIV with CD4 counts .200 cells/mm3
used fewer health services and the annual cost of services was less
than for PLHIV who had a CD4 count #200 cells/mm3 [18,19].
Based on the data presented, starting with a first-line NNRTI
regimen when CD4 count drops below 350 cells/mm3 currently is
the optimum first-line strategy [20–22] provided no specific
contra-indications exist. Current BHIVA and the new WHO
guidelines reflect this by recommending starting HAART when
the CD4 count drops below 350 cells/mm3 [23,24]. Until recently
US guidelines recommended a similar cut-off point to start
HAART [25], but the latest guidelines recommended starting
when CD4 count drops ,500 cells/mm3 [26]. Apart from the fact
that these last guidelines were not unanimously adopted, these
changes have also been questioned on the basis that the available
evidence is currently insufficient to determine if the adherence
challenges and long-term side-effects of early antiretroviral
treatment are outweighed by reduced risk of illness conferred by
these medicines when starting with a CD4 count ,500 cells/mm3
[27]. While a recent US study reported that hospitalization rates
for those on HAART with a CD4 count ,350 cells/mm3 did not
differ significantly from those with a CD4 count $350 cells/mm3
[28], more definitive answers to these questions will hopefully be
provided by the START study [29].
It remains a sobering finding that 55% of PLHIVs started
HAART with a CD4 count #200 cells/mm3, a disproportionate
number of whom were Black Africans compared with those who
started HAART with CD4 counts .200 cells/mm3. Having more
PLHIVs starting HAART with a CD4 count ,350 cells/mm3 will
increase the number of people receiving HAART, which will
initially add to the population cost of service provision [1].
Healthcare systems in many high-, middle- and low-income
countries are already under considerable financial strain, which
has been exacerbated by the global economic downturn [30].
However, starting PLHIVs on these cost-effective regimens earlier,
will maintain them in better health, resulting in them needing to
use fewer health or social services, thereby generating fewer
treatment and care costs, enabling them to remain socially and
economically active members of society and reducing population
costs in the medium- or long-term.
Some workers in the field maintain that through ‘test and treat
early’ strategies we may be able to eliminate the HIV pandemic
[31]. While the costs of such a strategy have been questioned [32]
and it is questionable whether this goal is achievable with current
treatment [33], the findings presented in this study provide social,
financial and economic arguments which strengthen the case for
HIV testing and earlier treatment strategies [34]. A recent
modelling study from the US suggests that expanding HIV testing
and starting early treatment with ART provide the greatest health
benefits and are cost-effective, although the authors concluded that
these measures in themselves are not sufficient to markedly reduce
the US epidemic and this also needs to be complemented by
successful behavioural strategies to stop people becoming newly
infected with HIV [35].
However stigma and discrimination remain strong disincentives
for people to come forward to be tested, especially if it involves
hard-to-reach key populations, so testing campaigns need to be
coupled to measures to ensure the confidentiality and security of
such personal information [2]. Furthermore, in countries with
limited resources this raises a number of ethical issues: should
those with most severe disease continue to be the first to receive
antiretroviral therapy? Should those with higher CD4 counts be
treated first, as they generate fewer costs by using fewer resources
and thereby enabling more PLHIVs to be treated or should
PLHIV receive HAART on a ‘first come and first-serve basis’? In
addition the assumption that antiretroviral treatment is for life as
accepted in high income countries [36] may also be questioned. It
is neither the intention nor the place of this paper to provide
answers to these questions as countries will need to develop and
implement their own context specific solutions. However, if these
broader aspects are not considered and successfully addressed,
early ‘test and treat’ may turn out to be more of a ‘trick’ than a
‘treat’.
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